Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Am J Transplant. 2017 Jan 25;17(6):1574–1584. doi: 10.1111/ajt.14161

Figure 3. Patient and Allograft Survival.

Figure 3

Patients with de novo DSA had reduced death-censored allograft survival, p= 0.01. At the end of follow-up, the actuarial death-censored allograft survival was 87.0% in the patients who developed dnDSA and 97.0% in patients who did not develop dnDSA, p=0.01. Cox regression with a time-dependent variable (dnDSA) was used to compare groups (Wald’s test at the 0.05 level).